IVVD Invivyd
Price Chart
Executive Summary
Invivyd completed enrollment in the Phase 3 DECLARATION trial evaluating VYD2311 for prevention of symptomatic COVID-19. Top-line results are expected in late Q3 2026. The trial was upsized by ~500 subjects to enhance statistical power.
Actionable Insight
Monitor for top-line results in late Q3 2026. Enrollment completion reduces clinical timeline risk, but no efficacy data yet. Stock may trade on trial catalysts and COVID wave dynamics over the summer.
Key Facts
- Enrollment completed in DECLARATION trial evaluating VYD2311 for COVID-19 prevention.
- Trial is BLA-enabling, Phase 3, randomized, placebo-controlled with ~2,400 participants.
- Sample size re-estimation added ~500 subjects to enhance statistical power.
- Top-line results expected approximately late Q3 2026.
Financial Impact
No financial data provided; successful Phase 3 data and potential BLA approval could be transformative for this pre-revenue company.
Risk Factors
- Trial failure or negative efficacy/safety data could severely impact stock.
- Regulatory hurdles for BLA submission and approval.
- Competition from vaccines and other monoclonal antibodies.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304208 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
4d ago
|
Press Release
| $1.22 $1.14 | ▼ −6.56% | ▼ −6.70% | $1.03 (−15.57%) |
|
May 14, 2026
22d ago
|
8-K
| — | awaiting T+1 | — | — |
|
May 14, 2026
22d ago
|
Press Release
| $1.16 $1.21 | ▲ +4.31% | ▲ +5.54% | $1.03 (−11.21%) |
|
Apr 9, 2026
8w ago
|
8-K
| $1.78 $1.76 | ▼ −1.12% | ▼ −1.06% | $1.03 (−42.13%) |
|
Apr 9, 2026
8w ago
|
Press Release
| $1.78 $1.76 | ▼ −1.12% | ▼ −1.06% | $1.03 (−42.13%) |
|
Apr 7, 2026
8w ago
|
Press Release
| $1.29 $1.35 | ▲ +4.65% | ▲ +2.11% | $1.03 (−20.16%) |
|
Mar 5, 2026
13w ago
|
8-K
| $1.74 $1.80 | ▲ +3.45% | ▲ +4.76% | $1.03 (−40.80%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $1.74 $1.80 | ▲ +3.45% | ▲ +4.76% | $1.03 (−40.80%) |
|
Mar 2, 2026
13w ago
|
Press Release
| $1.62 $1.71 | ▲ +5.56% | ▲ +4.79% | $1.03 (−36.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access